SURPASS-CVOT and the Case for Dual Incretin Therapy

Luke Laffin, MD, and Steven Nissen, MD, discuss findings from SURPASS-CVOT, including a secondary analysis evaluating broader cardiovascular and renal outcomes with dual GLP-1 and GIP agonist therapy compared with a first-generation GLP-1 agent. The conversation examines outcomes of the therapy on all-cause mortality and the clinical implications for treating patients with diabetes and high cardiovascular risk.

View current clinical trials. https://my.clevelandclinic.org/departments/heart/clinical-trials

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.